Aspira Women’s Health Inc. (NASDAQ:AWH) Short Interest Update

Aspira Women’s Health Inc. (NASDAQ:AWH) was the recipient of a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 537,600 shares, an increase of 20.4% from the October 15th total of 446,600 shares. Based on an average trading volume of 100,200 shares, the short-interest ratio is presently 5.4 days. Approximately 4.9% of the shares of the company are sold short.

Analyst Ratings Changes

Several research analysts have weighed in on the company. StockNews.com started coverage on Aspira Women’s Health in a research note on Wednesday. They issued a “hold” rating on the stock. Alliance Global Partners dropped their price objective on shares of Aspira Women’s Health from $7.00 to $5.50 and set a “buy” rating on the stock in a research note on Wednesday, August 14th.

Aspira Women’s Health Stock Performance

Shares of NASDAQ:AWH opened at $0.75 on Friday. Aspira Women’s Health has a 52 week low of $0.72 and a 52 week high of $5.65. The company has a 50-day moving average price of $0.85 and a 200 day moving average price of $1.42.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Aspira Women’s Health stock. B. Riley Wealth Advisors Inc. boosted its stake in shares of Aspira Women’s Health Inc. (NASDAQ:AWH) by 88.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 236,396 shares of the company’s stock after buying an additional 111,022 shares during the quarter. B. Riley Wealth Advisors Inc. owned 1.90% of Aspira Women’s Health worth $352,000 as of its most recent filing with the Securities and Exchange Commission. 12.19% of the stock is owned by institutional investors and hedge funds.

About Aspira Women’s Health

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.